Arizona Tribune - InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field

NYSE - LSE
SCS 0.12% 16.14 $
RBGPF 1.65% 83.78 $
BCC 0.63% 80.81 $
CMSD -0.17% 24.05 $
BCE 1.43% 25.86 $
CMSC 0.21% 23.76 $
GSK 1.82% 51.6 $
RIO -4.5% 91.03 $
NGG 0.23% 85.27 $
JRI 1.07% 13.08 $
RELX -1.03% 35.8 $
RYCEF -2.69% 16 $
AZN 0.19% 92.77 $
BTI 0.76% 60.68 $
BP -0.42% 37.88 $
VOD -0.41% 14.65 $
InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field
InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field

InnerMost Launches to Evolve Psychedelic Therapy - Advancing Treatment, Access, and Knowledge in the Field

Uniting FDA-authorized trials, ketamine and Spravato therapy, therapist training, and community education under one roof, InnerMost brings a vital new resource, contributing to the field globally

Text size:

NEW YORK, NY / ACCESS Newswire / November 21, 2025 / InnerMost PBC, New York City's new psychedelic-assisted therapy center dedicated to accessible care, practitioner training, FDA-authorized clinical trials, and community building, is officially open.

A public benefit corporation, InnerMost provides accessible ketamine and Spravato therapy, is an FDA-trial site that trains psychedelic-assisted therapists, and builds community amongst clinicians in this paradigm-shifting field.

With mental health needs at an all-time high, and uncertainty across politics and research, its launch introduces a hub for evidence-based psychedelic care-supporting New Yorkers while advancing access and progress globally. New hope emerges as the mainstream embraces new evidence-based approaches that expand what's possible in mental health care.

Leading conversations about psychedelic therapy's past, present and future is Casey Paleos, MD, (CV) Co-Founder & Chief Medical Officer, board-certified psychiatrist and researcher with 15+ years in psychedelic-assisted therapy. As figures like Rick Doblin pass the baton, they sing praises about his body of work and vision:

  • Principal Investigator, MAPS MDMA therapy for PTSD Studies

  • Therapist, NYU Psilocybin Cancer Anxiety Study

  • Co-Founder, Nautilus Sanctuary

  • Founding Board Member, International Alliance of MDMA Practitioners

  • Presenter, "Understanding Ketamine" Workshop, Psychotherapy Networker conference, Washington, D.C.

  • Co-Author of "Inner-Directed Therapy in MDMA-Assisted Psychotherapy," newly released commentary on the MDMA debate in the American Journal of Psychiatry

WHY INNERMOST IS DIFFERENT:

  • Research:FDA-authorized clinical trial site, including ongoing MDMA research and more TBA.

  • Treatment: Integration of psychotherapy with ketamine, Spravato, and future integrative mental health modalities.

  • Training: Practicum training, mentorship and clinical supervision.

  • Education & Community: Public programming, podcasts, panels, and partnerships.

  • Accessibility: Public benefit corporation whose mission is to eliminate socioeconomic barriers to accessing psychedelic therapies.

VISUALS:

  • First look at InnerMost's space and design.

  • Interviews with Dr. Paleos and team.

  • Photo and video opportunities.

Now open to the public by appointment at innermost.one, media are invited to schedule private tours of InnerMost.

MEDIA CONTACT: Marissa Feinberg | [email protected] | 917-494-5041

SOURCE: InnerMost



View the original press release on ACCESS Newswire

M.King--AT